Bookmark and Share

Debra R Counts
 

Debra R Counts M.D.

Academic Title: Associate Professor
Primary Appointment: Pediatrics
Administrative Title: Associate Chair For Clinical Affairs, Division Head
Additional Title(s): Division Chief, Pediatric Endocrinology
dcounts@peds.umaryland.edu
Location: UMMC, N6W84
Phone: (410) 328-3410
Phone: (410) 328-3412
Fax: (410) 328-0679
Lab: (410) 706-0188

Personal History:

* Medical school at Johns Hopkins University
* Pediatrics residency at Johns Hopkins Hospital.
* Fellowship in Pediatric Endocrinology at Washington University of St. Louis.
* Post-doctoral fellowship at NIH (NICHD/DEB).
* Faculty appointment at UMB since 1993.
* Division Head of Pediatric Endocrinology since 1995.

Research Interests:

1. Prevention of Type 1 diabetes - clinical trials with TrialNet and Immune Tolerance Network
2. Growth in short stature - basic science and clinical trials

Clinical Speciality:

1. Growth

2. Prader Willi syndrome

3. Pediatric Diabetes


Publications:

Selected Publications

Counts DR, Palese TA. A Novel Polymorphism In Exon 4 Of The Growth Hormone Gene And Association Of Short Stature With A Known 5' UTR Polymorphism. Journal of Endocrine Genetics 2(1):55-60, 2001.

Counts DR. An Adult with Prader-Willi syndrome and Anorexia Nervosa: a Case Report. International Journal of Eating Disorders, 30(2):231-33, 2001.

Young-Hyman D, Schlundt DG, Herman L, De Luca F, Counts D. Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children. Diabetes Care 2001 Aug;24(8):1359-64 19. Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, Eskenazi A, Helman L, Wexler LH. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001 Dec 1;92(11):2941-7

White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiolgy of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial Effects of Intensive Therapy of Diabetes During Adolescence: Outcomes After the Conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001 Dec:139(6):804-12.

Quevedo MF, Pironis B, Palese T, Counts DR, De Luca F. TSH secetory pattern and thyroid function in children with growth hormone neurosecretory dysfunction. J Pediatr Endocrinol Metab 15(4):377-80, Apr 2002.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
JAMA. 2002 May 15;287(19):2563-9.

Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF; DCCT/EDIC Research Group. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002 Oct;105(1):81-92.

Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF; DCCT/EDIC Research Group. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar;44(3):487-93. Epub 2002 Dec 01.

Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL; DCC/EDIC Research Group. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar;26(3):810-8.

Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH; DCCT/EDIC Study Group. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes. 2003 May;52(5):1215-21.

Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey WT;
DCCT/EDIC Study Group. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care. 2003 May;26(5):1439-48.

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003 Jun 5;348(23):2294-303.

Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL;
DCCT/EDIC Study Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003 Sep;64(3):817-28.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003 Oct 22;290(16):2159-67.

Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler AJ, Brown WV, Lyons TJ, Garvey WT; DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004 Oct;53(10):1296-304.

Watson DC, Counts DR. Growth hormone deficiency in HIV-infected children following successful treatment with highly active antiretroviral therapy. J Pediatr. 2004 Oct;145(4):549-51.

Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT; DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications. 2005 Jan-Feb;19(1):18-25.

Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, England J, Bucksa J, Nowicki M. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem. 2005 Apr;51(4):753-8. Epub 2005 Jan 31.

Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B; DCCT/EDIC Research Group. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes. 2005 Apr;54(4):1238-44.

Tsai EB, Sherry NA, Palmer JP, Herold KC; for the DPT-1 Study Group. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006 Jan 11;:1-10

Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J; DPT-1 study group. High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes. Diabetologia. 2005 Jan;48(1):68-74. Epub 2004 Dec 16.

Rhodes ET, Wolfsdorf JI, Cuthbertson DD, Feldman HA, Ludwig DS; DPT-1 Study Group. Effect of low-dose insulin treatment on body weight and physical development in children and adolescents at risk for type 1 diabetes. Diabetes Care. 2005 Aug;28(8):1948-53.

Sapone A, de Magistris L, Pietzak M, Clemente M, Triphati A, Lampis R, Kryszak D, Cartena, M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R', Counts D, Fasano A. Zonulin up-regulation is associated to increase in gut permeability without changes in tight junction protein genes expression in subjects with Type 1 diabetes and their relatives. Diabetes, 2006 May;55(5):1443-9.

Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, Leehealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences U S A. 2006 Nov 14;103(46):17414-17419. Epub 2006 Nov 6.

Rapaport R, Saenger P, Wajnrajch MP; Pfizer SGA Collaborative Study Group. Predictors of first-year growth response to a fixed-dose growth hormone treatment in children born small for gestational age: results of an open-label, multicenter trial in the United States. J Pediatr Endocrinol Metab. 2008 May;21(5):411-22.

Mahon JL, and the TrialNet Natural History Committee. Type 1 Diabetes, TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes. 2009 Apr;10(2):97-104. Epub 2008 Sep 24.

Skyler JS and the Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008 Dec;1150:190-6. Review.

Skyler JS, and the Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci. 2008 Dec;1150:14-24.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, et al Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16 46. Hypothyroidism in children. Counts D, Varma SK. Pediatr Rev. 2009 Jul;30(7):251-8. Review.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16.